UK markets closed
NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.88 -0.69 (-0.89%) GOLD FUTURES
2,329.80 -63.10 (-2.64%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
53,387.49 -1,311.63 (-2.40%)
Oncopeptides AB (publ) (0RN4.IL)
IOB - IOB Delayed price. Currency in SEK
Add to watchlist
At close: 12:30PM BST
| Previous close | 2.7150 |
| Open | 0.0000 |
| Bid | 2.6250 x N/A |
| Ask | 2.9000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 17,287 |
| Market cap | 277.417M |
| Beta (5Y monthly) | -0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e
© 2024 Yahoo. All rights reserved.